registHER: patient characteristics and time course of CNS metastases in patients with HER2-positive metastatic breast cancer.

被引：0
|
作者：
Yardley, D. A.
Kaufman, P. A.
Mayer, M.
Ulcickas, Yood M.
Tan-Chiu, E.
Brufsky, A. M.
Rugo, H. S.
Tripathy, D.
Brammer, M. G.
Paik, S.
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[3] Patient Advocate, New York, NY USA
[4] Yale Univ, Sch Med, EpiSource LLC, New Haven, CT USA
[5] Florida Canc Care, Tamarac, FL USA
[6] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA USA
[7] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[8] Univ Texas SW Med Ctr, Dallas, TX USA
[9] Genentech Inc, San Francisco, CA USA
[10] Natl Surg Breast & Bowel Project, Pittsburgh, PA USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S263 / S264
页数：2
相关论文
共 50 条
  • [21] The predictive potential of metastatic serum markers and circulating tumor cells in advanced HER2-positive breast cancer patients - Focused on CNS metastases
    Mikulova, V.
    Jancikova, M.
    Tesarova, P.
    Zima, T.
    CANCER RESEARCH, 2016, 76
  • [22] registHER: Results from a prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer.
    Rugo, HS
    Yardley, D
    Tan-Chiu, E
    Brufsky, A
    Kaufman, P
    Paik, S
    Ulcickas-Yood, M
    Mayer, M
    Tripathy, D
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S90 - S90
  • [23] First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER
    Tripathy, Debu
    Kaufman, Peter A.
    Brufsky, Adam M.
    Mayer, Musa
    Yood, Marianne Ulcickas
    Yoo, Bongin
    Quah, Cheng
    Yardley, Denise
    Rugo, Hope S.
    ONCOLOGIST, 2013, 18 (05): : 501 - 510
  • [24] Appearance and therapy of brain metastases in patients with HER2-positive breast cancer
    Witzel, I
    Hemminger, G.
    Ihnen, M.
    Jaenicke, F.
    Mueller, V
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S137 - S137
  • [25] Neratinib in HER2-Positive Breast Cancer With Brain Metastases
    Dekker, Tim Johannes Adrianus
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03) : 251 - +
  • [26] Treatment of brain metastases of HER2-positive breast cancer
    Heudel, P.
    Tredan, O.
    Cassier, P.
    Ray-Coquard, I.
    Guastalla, J. -P.
    Bachelot, T.
    ONCOLOGIE, 2012, 14 (01) : 41 - 44
  • [27] Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases
    Gori, S.
    Lunardi, G.
    Inno, A.
    Foglietta, J.
    Cardinali, B.
    Del Mastro, L.
    Crino, L.
    ANNALS OF ONCOLOGY, 2014, 25 (04) : 912 - 913
  • [28] Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab
    Muhammet Ali Kaplan
    Hamza Ertugrul
    Ugur Firat
    Mehmet Kucukoner
    Ali İnal
    Zuhat Urakci
    Zafer Pekkolay
    Abdurrahman Isikdogan
    Breast Cancer, 2015, 22 : 503 - 509
  • [29] Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab
    Kaplan, Muhammet Ali
    Ertugrul, Hamza
    Firat, Ugur
    Kucukoner, Mehmet
    Inal, Ali
    Urakci, Zuhat
    Pekkolay, Zafer
    Isikdogan, Abdurrahman
    BREAST CANCER, 2015, 22 (05) : 503 - 509
  • [30] Real World Data for Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases
    Toler, Andrew
    Bobolts, Laura R.
    Mangurian, Mark
    Pozotrigo, Melissa
    Wise, Corey
    Solomon, Hiywete
    Hartung, Nicole
    Makielski, Rory
    Marur, Shika
    Ravindranathan, Meera
    Marur, Shanthi
    CANCER RESEARCH, 2023, 83 (05)
12345